What question did this study set out to answer?

To assess whether a personalized neoantigen-targeting cancer vaccine, administered with or without adjacent ipilimumab, can generate antitumor immunity against key driver mutations and prevent disease recurrence in surgically resected renal cell carcinoma.

February 5, 2025NatureOpen Access

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

View Full Paper

Ask AI

Bookmark

Authors

DBDavid A. Braun GMGiorgia Moranzoni VCVipheaviny Chea

Discussion

Member takes

Overview

Phase I trial demonstrates zero recurrence and durable antitumor T-cell immunity in resected renal cell carcinoma, highlighting the efficacy of personalized neoantigen vaccines.

Key Points

To assess whether a personalized neoantigen-targeting cancer vaccine, administered with or without adjacent ipilimumab, can generate antitumor immunity against key driver mutations and prevent disease recurrence in surgically resected renal cell carcinoma.
Conducted a phase I interventional clinical trial (ClinicalTrials.gov identifier NCT02950766) testing a personalized cancer vaccine targeting predicted neoantigens with or without adjacent ipilimumab.
Enrolled 9 participants (N=9) with high-risk, fully resected stage III or IV clear cell renal cell carcinoma, followed for a median duration of 40.2 months post-surgery.
At a median follow-up of 40.2 months after surgery, 0 of 9 enrolled participants experienced disease recurrence, with no dose-limiting toxicities reported.
All 9 patients generated durable peripheral T cell immune responses against vaccine neoantigens, including specific driver mutations in VHL, PBRM1, BAP1, KDM5C, and PIK3CA.
Reactivity of circulating T cells against autologous tumor tissue was confirmed in 7 out of 9 patients.

Cite This Study

Braun et al. (2025) studied this question.

synapsesocial.com/papers/69d78d00ef4aa71f97f319df https://doi.org/10.1038/s41586-024-08507-5

View Full Paper

Ask AI

Bookmark

February 5, 2025NatureOpen Access

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

View Full Paper

Ask AI

Bookmark

Authors

DBDavid A. Braun GMGiorgia Moranzoni VCVipheaviny Chea

Discussion

Member takes

Overview

Phase I trial demonstrates zero recurrence and durable antitumor T-cell immunity in resected renal cell carcinoma, highlighting the efficacy of personalized neoantigen vaccines.

Key Points

To assess whether a personalized neoantigen-targeting cancer vaccine, administered with or without adjacent ipilimumab, can generate antitumor immunity against key driver mutations and prevent disease recurrence in surgically resected renal cell carcinoma.
Conducted a phase I interventional clinical trial (ClinicalTrials.gov identifier NCT02950766) testing a personalized cancer vaccine targeting predicted neoantigens with or without adjacent ipilimumab.
Enrolled 9 participants (N=9) with high-risk, fully resected stage III or IV clear cell renal cell carcinoma, followed for a median duration of 40.2 months post-surgery.
At a median follow-up of 40.2 months after surgery, 0 of 9 enrolled participants experienced disease recurrence, with no dose-limiting toxicities reported.
All 9 patients generated durable peripheral T cell immune responses against vaccine neoantigens, including specific driver mutations in VHL, PBRM1, BAP1, KDM5C, and PIK3CA.
Reactivity of circulating T cells against autologous tumor tissue was confirmed in 7 out of 9 patients.

Cite This Study

Braun et al. (2025) studied this question.

synapsesocial.com/papers/69d78d00ef4aa71f97f319df https://doi.org/10.1038/s41586-024-08507-5

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark